A Phase 1, Open-Label, Dose Escalation Study of ASG-5ME in Patients With Pancreatic or Gastric Adenocarcinoma

Inclusion Criteria:

- Pathologically confirmed metastatic pancreatic adenocarcinoma or pathologically
confirmed AGS-5-positive gastric or gastric esophageal junction adenocarcinoma

- Measurable disease (at least one nonresectable, non-nodal lesion greater than or
equal to 10 mm in longest diameter or nodal lesion greater than or equal to 15 mm in
shortest axis)

- ECOG performance status of 0 or 1

- May be untreated or have previously received treatment for pancreatic adenocarcinoma
or must have relapsed or refractory disease following 1 prior systemic therapy for
metastatic gastric adenocarcinoma. For patients who have previously received
treatment, it must be at least 2 weeks since the last systemic therapy or radiation,
and at least 4 weeks since treatment with any monoclonal antibody (other than
bevacizumab).

Exclusion Criteria:

- Evidence or history of central nervous system metastases

- History of another primary malignancy that has not been in remission for at least 3
years

- Documented history of a cerebral vascular event, unstable angina, myocardial
infarction, or cardiac symptoms consistent with NYHA Class III-IV within 6 months
prior